Latest revenue
$852.3K
as of 2025-09-30
Latest net income
$-809.4K
as of 2025-09-30
Net margin
-95.0%
as of 2025-09-30
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $23.2K
- Enterprise value
- $23.2K
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $0.04
- 52-wk low
- $0.00
- Beta
- —
- Shares out
- 232.0M
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
What this company does
Item 1: Description of Business Stemtech Corporation and its Subsidiaries (collectively, the “Company”, or “Stemtech”) was incorporated in the State of Nevada, USA on September 4, 2009 under the name Globe Net Wireless Corp. with ticker symbol “GNTW”. Our corporate name was changed to Stemtech Corporation in the state of Nevada.in August 2021. We were listed on the OTCQB market under symbol “STEK” in April 2021. Stemtech is a global network marketing company that develops science-based products that it believes supports wellness by helping the body maintain healthy stem cell physiology, also known as stem cell enhancers. Known as the Stem Cell Nutrition Company®, the Company is a pioneer in…
AI summary unavailable — showing raw filing excerpt
Generated from STEK's filing dated 2025-06-30
Key risks
Item 1A. Risk Factors. We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.
AI summary unavailable — showing raw filing excerpt
Generated from STEK's filing dated 2025-06-30
Profitability
Gross margin
73.8%
7.4%Operating margin
-47.2%
45.0%Net margin
-74.6%
32.4%Return on equity
84.1%
68.4%Return on assets
-99.7%
32.4%Leverage
Debt / equity
-1.84×
34.3%Long-term debt / equity
0.00×
Debt / assets
218.6%
40.7%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q3 2025 2025-09-30 | $852.3K | -17.4% | $-809.4K | +30.8% | -95.0% |
Q2 2025 2025-06-30 | $697.9K | -47.4% | $-293.1K | +62.6% | -42.0% |
Q1 2025 2025-03-31 | $868.0K | -37.2% | $-1.5M | -2.6% | -167.7% |
Q4 2024 2024-12-31 | $1.3M | — | $-396.6K | — | -30.2% |
Q3 2024 2024-09-30 | $1.0M | -20.5% | $-1.2M | -12.4% | -113.5% |
Q2 2024 2024-06-30 | $1.3M | +17.5% | $-784.2K | -173.3% | -59.1% |
Q1 2024 2024-03-31 | $1.4M | — | $-1.4M | — | -102.6% |
Q3 2023 2023-09-30 | $1.3M | — | $-1.0M | — | -80.2% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Wholesale-Drugs, Proprietaries & Druggists' Sundries · SIC 5122
Your notes
Keep private notes on STEK — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$30.0K
Net activity
−$30.0K
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns STEK
No institutional holdings on file for STEK yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once STEK's latest filing finishes processing.